enGene Therapeutics (ENGN) director awarded 31,000 stock options

Rhea-AI Filing Summary

enGene Therapeutics Inc. director Paul J. Hastings received a grant of stock options for 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HASTINGS PAUL J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 31,000 options Exercise price: $1.75 per share Expiration date: June 16, 2036 +2 more

5 metrics

Stock options granted 31,000 options Grant to director Paul J. Hastings

Exercise price $1.75 per share Strike price of granted options

Expiration date June 16, 2036 Option term end

Underlying shares 31,000 common shares Shares purchasable upon exercise

Holdings after grant 31,000 derivative securities Total options following transaction

Key Terms

Stock Option (Right to Buy), vesting commencement date, annual meeting of shareholders, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

vesting commencement date financial

"the first anniversary of the vesting commencement date, which was June 9, 2026"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of shareholders financial

"or (ii) the registrant's 2027 annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 05:40 PM Accepted by SEC EDGAR 06/17/2026 - 05:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HASTINGS PAUL J

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT H4R 2P1

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.75	06/16/2026		A		31,000		(1)	06/16/2036	Common Shares	31,000	$0	31,000	D

Explanation of Responses:

1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

	/s/ Lee Giguere, as attorney-in-fact for the Reporting Person	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did enGene Therapeutics (ENGN) report for Paul J. Hastings?

enGene Therapeutics reported that director Paul J. Hastings received a grant of stock options for 31,000 common shares. This is a compensation-related award, not an open-market share purchase or sale, and reflects equity-based incentives tied to the company’s performance.

How many enGene Therapeutics (ENGN) options were granted to Paul J. Hastings?

Paul J. Hastings was granted stock options covering 31,000 common shares of enGene Therapeutics. These options give him the right to buy that number of shares at a fixed exercise price, subject to the vesting schedule and expiration date disclosed in the filing.

What is the exercise price of Paul J. Hastings’ enGene Therapeutics (ENGN) stock options?

The granted stock options have an exercise price of $1.75 per common share. This means Hastings can purchase shares at $1.75 once the options vest and before they expire, aligning his potential upside with future changes in the company’s share price.

When do Paul J. Hastings’ enGene Therapeutics (ENGN) options vest?

The options vest fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting. This single-vesting schedule ties the award to both time-based service and a key corporate governance event.

When do Paul J. Hastings’ enGene Therapeutics (ENGN) stock options expire?

The options granted to Paul J. Hastings expire on June 16, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase enGene Therapeutics common shares, limiting the time window for exercising the award.

Is Paul J. Hastings’ enGene Therapeutics (ENGN) option grant an open-market transaction?

No, the Form 4 describes a grant or award acquisition of stock options, not an open-market trade. The transaction code "A" and zero purchase price indicate a compensation grant rather than buying or selling shares on the public market.